Poland· PL-100511402
Elahere
A mirvetuximab soravtansine product containing mirvetuximabum soravtansinum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mirvetuximab soravtansine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX26 (mirvetuximab soravtansine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Mirvetuximab soravtansine · ATC L01FX26
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Mirvetuximabum soravtansinum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- L01FX26
- ATC class
- Mirvetuximab soravtansine
- Defined daily dose
- 18 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08054083029306
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirvetuximab soravtansine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElahere 5 mg/mlAbbVie Deutschland
- CzechiaELAHEREAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- FinlandELAHEREAbbVie Deutschland GmbH&Co.KG
- IrelandELAHERE 5 mg/mL concentrate for solution for infusionImmunogen Biopharma (Ireland) Limited
- IcelandELAHEREAbbVie Deutschland GmbH & Co. KG
- NorwayElahereAbbVie Deutschland GmbH & Co
- SwedenELAHERE 5 mg/ml Koncentrat till infusionsvätska, lösningAbbVie Deutschland GmbH & Co KG
- SwitzerlandElahere
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Elahere
- Iceland · Elahere
- Liechtenstein · Elahere
- Norway · Elahere
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9ca7564c-8bc3-42f9-8942-471286ee20e2 GET /v1/drugs/9ca7564c-8bc3-42f9-8942-471286ee20e2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "5 mg/ml",
"packaging": "08054083029306 ¦ Rpz ¦ EU/1/24/1866/001 ¦ 159831\n1 fiol. 20 ml",
"substance": "Mirvetuximabum soravtansinum 5 mg/ml",
"common_name": "Mirvetuximabum soravtansinum",
"pl_product_id": "100511402",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about mirvetuximab soravtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.